J&J/Medivir’s Simeprevir Review Makes For Back-To-Back Hep C Advisory Committees
This article was originally published in The Pink Sheet Daily
Executive Summary
Like Merck’s boceprevir and Vertex’s telaprevir in 2011, simeprevir and Gilead’s sofosbuvir both have been accepted as priority review candidates for hepatitis C therapy, and will be reviewed by FDA’s Antiviral Drugs Advisory Committee on consecutive days. A positive tone is anticipated at both panel meetings.